Tumor suppressor and anti-inflammatory protein: an expanded view on insulin-degrading enzyme (IDE)
Razvan Tudor Radulescu

TL;DR
This paper expands the understanding of insulin-degrading enzyme (IDE) as a tumor suppressor and anti-inflammatory protein, revealing structural features that enable it to inhibit inflammation and cancer progression through multiple mechanisms.
Contribution
It uncovers new structural motifs in IDE that suggest its role in suppressing inflammation and tumor growth, broadening its functional scope beyond insulin degradation.
Findings
IDE contains ankyrin repeat-like sequences that may bind NF-kappaB and CDKs.
IDE has RXL motifs that could inhibit cyclin-dependent kinases.
Structural homology links IDE to tumor suppressor RB, supporting its anti-cancer role.
Abstract
In 1994, I conjectured that insulin-degrading enzyme (IDE) acts as an inhibitor of malignant transformation by degrading insulin and thus preventing this major growth-stimulatory hormone from binding and thereby inactivating the retinoblastoma tumor suppressor protein (RB). Ten years later, I discovered that a carboxyterminal RB amino acid sequence resembles the catalytic center of IDE. This structural homology raised the possibility that insulin degradation is a basic mechanism for tumor suppression shared by RB and IDE. Subsequently, a first immunohistochemical study on the differential expression of human IDE in normal tissues, primary tumors and their corresponding lymph node metastases further corroborated the initial conjecture on IDE being an antineoplastic molecule. In this report, it is shown that IDE harbors ankyrin repeat-like amino acid sequences through which it might bind…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRetinoids in leukemia and cellular processes · Cancer-related Molecular Pathways · Peroxisome Proliferator-Activated Receptors
